DRY EYE: Bolstering the tear film - Scorecard - MDSpire

DRY EYE: Bolstering the tear film

Let’s discuss interventions to improve the tear film.

  • By

  • Pamela E. Theriot, OD, FAAO

  • January 1, 2025

  • 5 min

Share

Clinical Scorecard: DRY EYE: Bolstering the tear film

At a Glance

CategoryDetail
ConditionDry Eye Disease (DED)
Key MechanismsCompromise of the lacrimal functional unit affecting tear secretion.
Target PopulationContact lens wearers experiencing discomfort due to dry eye.
Care SettingOphthalmology practices and specialty dry eye clinics.

Key Highlights

  • Dry eye disease decreases contact lens tolerability.
  • Improving tear film is essential for long-term contact lens wear.
  • Meibomian gland dysfunction is prevalent in 30% to 60% of contact lens wearers.
  • Multiple treatment options are available to enhance tear volume and lipid layer.
  • Reducing toxic load from contact lens solutions can alleviate symptoms.

Guideline-Based Recommendations

Diagnosis

  • Assess ocular surface issues and symptoms of dry eye disease.

Management

  • Utilize medications such as cyclosporine and liftegrast to increase tear volume.
  • Implement at-home therapies like warm compresses and eyelid hygiene.

Monitoring & Follow-up

  • Regularly evaluate contact lens wear time and comfort.

Risks

  • Toxicity from contact lens solutions can exacerbate dry eye symptoms.

Patient & Prescribing Data

Patients with dry eye disease who wear contact lenses.

Consider both pharmacological and non-pharmacological interventions to manage symptoms.

Clinical Best Practices

  • Encourage daily disposable lenses and preservative-free care systems.
  • Educate patients on the importance of maintaining a healthy tear film.
  • Monitor for meibomian gland dysfunction and address it promptly.

References

Original Source(s)

DRY EYE: Bolstering the tear film

  • by Pamela E. Theriot, OD, FAAO

  • January 1, 2025

Related Content

Industry Insider

Julie Brewer discusses her role as senior vice president, president, global franchises at Alcon.

  • January 1, 2026

  • 5 min
Profitable Presbyopia

Presbyopia is no longer a condition we simply accommodate; it has become a platform for a longitudinal relationship that can span decades.

Study Provides Real-World Evidence for Inflammatory DED

Carolina L. Mercado, MD, and colleagues presented data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry linked to pharmacy claims data sourced from the Komodo Health Research Dataset.